SBC Medical Group Holdings (SBC) AI Stock Analysis

• Market Cap: $458.52M
• Dividend Yield: N/A
• Average Volume (3M): 65.67K
• Price to Earnings (P/E): 10.6
• Beta (1Y): 0.77
• Revenue Growth: 236.18%
• EPS Growth: N/A
• Country: US
• Employees: 863
• Sector: Industrials
• Sector Strength: 72
• Industry: Consulting Services
• EPS (TTM): 0.12
• Shares Outstanding: 102,576,940
• 10 Day Avg. Volume: 48,167
• 30 Day Avg. Volume: 65,672
• PEG Ratio: 0.50
• Price to Book (P/B): 2.75
• Price to Sales (P/S): 2.61
• P/FCF Ratio: 31.26
• Enterprise Value/Market Cap: 0.75
• Enterprise Value/Revenue: 1.92
• Enterprise Value/Gross Profit: 2.61
• Enterprise Value/Ebitda: 4.73
• 1Y Price Target: $9.00
• Price Target Upside: 105.48% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 75 Outperform
• Price Target: $5.00 ▲(14.16% Upside)

SBC Medical Group Holdings scores well due to its strong valuation and strategic acquisition, which enhances its market position. However, operational challenges reflected in financial performance and technical indicators showing overbought conditions slightly temper the overall score.

Positive Factors

Strategic Acquisition

The acquisition of Waqoo significantly boosts SBC's capabilities in healthcare technology and solidifies its market position in Japan, providing long-term growth opportunities and competitive advantages in the region.

Profitability

An improving net profit margin indicates strong operational efficiency and effective cost management, which can enhance long-term profitability and shareholder value.

Balance Sheet Health

A low debt-to-equity ratio reflects prudent financial management, providing SBC with financial flexibility to invest in growth opportunities and weather economic downturns.

Negative Factors

Declining Revenue Growth

A decline in revenue growth suggests potential challenges in maintaining market share or product demand, which could impact long-term business expansion and profitability.

Negative Operating Cash Flow

Negative operating cash flow indicates potential difficulties in generating cash from core operations, which could strain liquidity and limit investment in growth initiatives.

Revenue Growth Challenges

The combination of declining revenue growth and negative operating cash flow highlights operational challenges that may hinder SBC's ability to sustain growth and profitability in the long term.

SBC Medical Group Holdings Business Overview & Revenue Model

Company Description

SBC Medical Group Holdings (SBC) is a healthcare organization focused on delivering innovative medical solutions and services across various sectors, including pharmaceuticals, medical devices, and healthcare technology. The company specializes in developing and distributing products that enhance patient care and improve clinical outcomes. With a commitment to research and development, SBC strives to address unmet medical needs through its core offerings, which include advanced therapeutics, diagnostic tools, and integrated healthcare solutions.

How the Company Makes Money

SBC Medical Group Holdings generates revenue through multiple streams, primarily by selling its pharmaceutical products, medical devices, and healthcare technology solutions to hospitals, clinics, and healthcare providers. The company earns money from direct sales of its proprietary products as well as through licensing agreements and partnerships with other healthcare organizations. Additionally, SBC may engage in collaborations with research institutions for the development of new therapies, which can lead to revenue from shared intellectual property rights. The company's strong emphasis on research and development allows it to stay competitive in the market, attracting investment and funding for innovative projects, further contributing to its earnings.

SBC Medical Group Holdings Financial Statement Overview

Summary

SBC Medical Group Holdings shows strong profitability and a robust balance sheet with low leverage and effective equity utilization. However, declining revenue growth and negative operating cash flow in TTM highlight potential operational challenges.

Income Statement

SBC Medical Group Holdings shows strong profitability with a consistent gross profit margin above 70% and a net profit margin improving to 24.28% in TTM. However, the revenue growth rate has declined by 5.17% in TTM, indicating potential challenges in maintaining top-line growth.

Balance Sheet

The company maintains a solid balance sheet with a low debt-to-equity ratio of 0.11 in TTM, reflecting prudent financial management. Return on equity remains healthy at 18.96%, though slightly lower than previous years, indicating effective use of equity to generate profits.

Cash Flow

Cash flow metrics present a mixed picture. The free cash flow growth rate is positive at 210.12% in TTM, but operating cash flow is negative, raising concerns about cash generation from operations. The free cash flow to net income ratio is strong at 1.06, suggesting good cash conversion from profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	178.46M	205.42M	193.54M	174.16M
Gross Profit	131.52M	156.05M	137.30M	114.83M
EBITDA	72.59M	77.28M	85.87M	29.64M
Net Income	43.32M	46.61M	39.37M	6.32M
Balance Sheet
Total Assets	321.36M	266.08M	258.81M	225.48M
Cash, Cash Equivalents and Short-Term Investments	127.43M	125.04M	103.02M	53.64M
Total Debt	28.15M	12.21M	22.87M	16.13M
Total Liabilities	73.30M	71.06M	115.00M	117.63M
Stockholders Equity	247.99M	195.11M	142.16M	105.25M
Cash Flow
Free Cash Flow	-36.63M	17.17M	39.44M	-24.99M
Operating Cash Flow	-34.60M	20.58M	50.64M	-47.37K
Investing Cash Flow	-1.31M	-10.10M	1.82M	-32.65M
Financing Cash Flow	29.85M	22.97M	6.14M	-7.98M

SBC Medical Group Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBC, the sentiment is Positive. The current price of 4.38 is above the 20-day moving average (MA) of 4.03, above the 50-day MA of 3.69, and above the 200-day MA of 4.05, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 66.41 is Neutral, neither overbought nor oversold. The STOCH value of 80.39 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBC.

SBC Medical Group Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRAI	78 Outperform	$1.37B	25.04	27.83%	0.97%	8.69%	34.58%
SBC	75 Outperform	$458.52M	10.56	19.13%	―	236.18%	―
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
FC	59 Neutral	$203.47M	71.26	4.09%	―	-7.02%	-86.27%
RGP	51 Neutral	$174.30M	-0.92	-61.44%	6.74%	-10.83%	-1669.11%
FORR	42 Neutral	$137.01M	-1.61	-43.39%	―	-8.73%	-1168.15%
AERT	39 Underperform	$26.26M	-24.77	―	―	-3.87%	-104.63%

SBC Medical Group Holdings Corporate Events

SBC Medical Completes Acquisition of Waqoo Shares

On December 13, 2025, SBC Medical Group Holdings announced the final results of its tender offer for Waqoo, Inc., a Japanese medical R&D company specializing in regenerative medicine. The tender offer, conducted from November 14 to December 12, 2025, resulted in SBC Medical acquiring 575,052 shares at ¥1,900 per share. This acquisition, along with an off-market transaction with Waqoo’s largest shareholder, will increase SBC Medical’s ownership to over 50%, making it the parent company and largest shareholder of Waqoo. This strategic move enhances SBC’s healthcare technology capabilities and strengthens its presence in the Japanese market.

SBC Medical Group Announces Tender Offer for Waqoo

On November 13, 2025, SBC Medical Group Co., Ltd., a subsidiary of SBC Medical Group Holdings, announced the commencement of a tender offer to acquire shares of Waqoo, Inc., a Japanese corporation listed on the Tokyo Stock Exchange Growth Market. The tender offer, running from November 14 to December 12, 2025, aims to purchase up to 575,000 shares, with settlement expected on December 19, 2025. This strategic move is part of SBC’s plan to make Waqoo a consolidated subsidiary, enhancing its research and development initiatives and integrating Waqoo’s advanced technologies into SBC’s offerings. This acquisition is expected to strengthen SBC’s competitiveness in clinical areas such as AGA and orthopedics and support the development of new treatment methods and proprietary services.